The physical burden of prostate cancer

被引:31
作者
Penson, DF
Litwin, MS
机构
[1] VAPSHCS, Urol Sect, Seattle, WA 98108 USA
[2] Univ Washington, Sch Med, Seattle, WA 98195 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA 90095 USA
关键词
D O I
10.1016/S0094-0143(02)00187-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Prostate cancer remains the most frequently diagnosed solid tumor and the second leading cause of death among American men. In the past decade there has been a steady decrease in the average age at diagnosis. The shift toward earlier age at diagnosis means that prostate cancer survivors will have longer life expectancies after diagnosis, regardless of treatment, and will therefore have more time to experience the physical, psychologic, and economic burdens of this highly prevalent malignancy. The shift toward earlier age at diagnosis means that prostate cancer survivors win have longer life expectancies after diagnosis, regardless of treatment, and win therefore have more time to experience the physical, psychologic, and economic burdens of this highly prevalent malignancy.
引用
收藏
页码:305 / +
页数:10
相关论文
共 63 条
[1]  
Adib RS, 1997, BRIT J UROL, V79, P235
[2]   Health-related quality of life among patients with metastatic prostate cancer [J].
Albertsen, PC ;
Aaronson, NK ;
Muller, MJ ;
Keller, SD ;
Ware, JE .
UROLOGY, 1997, 49 (02) :207-216
[3]  
[Anonymous], 1999, Prostate Cancer Trends 1973-1995
[4]  
Arterbery VE, 1997, SEMIN SURG ONCOL, V13, P461, DOI 10.1002/(SICI)1098-2388(199711/12)13:6<461::AID-SSU11>3.0.CO
[5]  
2-W
[6]   Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study [J].
Boccardo, F ;
Rubagotti, A ;
Borichello, M ;
Battaglia, M ;
Carmignani, G ;
Comeri, G ;
Conti, G ;
Cruciani, G ;
Dammino, S ;
Delliponti, U ;
Ditonno, P ;
Ferraris, V ;
Lilliu, S ;
Montefiore, F ;
Portoghese, F ;
Spano, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2027-2038
[7]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[8]   Intermittent androgen suppression in the treatment of metastatic prostate cancer [J].
Bouchot, O ;
Lenormand, L ;
Karam, G ;
Prunet, D ;
Gaschignard, N ;
Malinovsky, JM ;
Buzelin, JM .
EUROPEAN UROLOGY, 2000, 38 (05) :543-549
[9]   Quality of life outcomes after brachytherapy for early stage prostate cancer [J].
Brandeis, JM ;
Litwin, MS ;
Burnison, CM ;
Reiter, RE .
JOURNAL OF UROLOGY, 2000, 163 (03) :851-857
[10]   PATIENTS CHOICE OF TREATMENT IN STAGE-D PROSTATE-CANCER [J].
CASSILETH, BR ;
SOLOWAY, MS ;
VOGELZANG, NJ ;
SCHELLHAMMER, PS ;
SEIDMON, EJ ;
HAIT, HI ;
KENNEALEY, GT .
UROLOGY, 1989, 33 (05) :57-62